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Abstract 
To determine the effectiveness of a single or a combination of topical neurotrophic 
factors (NFs) in protecting retinal ganglion cells (RGCs) in the rat optic nerve crush 
(ONC) model, the left ONC was performed to induce the death of the RGCs in adult 
Sprague-Dawley rats. The NFs studied were tauroursodeoxycholic acid (TUDCA), 
citicoline, neurotrophin-4 (NT-4), combined TUDCA/citicoline (Doublet-1), combined 
TUDCA/NT-4 (Doublet-2), combined TUDCA/citicoline/NT-4 (Triplet), and PBS. After 2 
weeks, the number of RGCs was determined by Brn3a immunostaining. The 
optic nerves were immunostained for anti-Growth Associated Protein-43(GAP-43) 
and -200kD neurofilament heavy chain antibody to study optic nerve regeneration. Two 
weeks after ONC, the densities of RGCs in all treated eyes except NT-4 group were 
significantly higher than those of the PBS treated eyes. In the Triplet group, the number of 
RGC axons after ONC was significantly higher than that in all of the single treatment 
groups. The number of TUNEL positive cells was significantly reduced and the 
number of GAP-43 immunopositive axons was significantly greater in the Triplet group 
compared with the PBS group. Neovascularization was observed only in the Doublet-1 
group. We conclude that the combination of the three NFs was the most effective way to 
protect RGCs after ONC. 
 
There is an accumulation of glycated proteins, nucleic acid, and lipids with 
increasing age which results from the elevated blood glucose. These changes 
increase the oxidative stress which then triggers further modifications of the 
proteins, and the onset of neural and vascular complications 1. The results 
of our recent study showed that glycation is involved in the pathogenesis of retinal 
diabetic neuropathy, and it acts by triggering different mechanisms resulting in 
neuronal dysfunction 2-6. Caspase-dependent and caspase-independent cell death 
pathways were confirmed to be involved in the apoptosis of retinal ganglion cells 
(RGCs) in the presence of very low doses of advanced glycation end products 
(AGEs) 4. Additionally, an expression of the receptors of the AGE (RAGE) genes 
indicated that there was an increase in the expression of transcription factors NF-kB 
and SP1 in AGEs-exposed retinas 5. These findings suggested that a strategy for 
treating neurodegenerative diseases might be obtained by determining the genes 
and pathways involved in neurodegeneration. We determined earlier that neuroprotective 
and regenerative factors such as neurotrophin-4 (NT-4) 4,7, citicoline 8, 
tauroursodeoxycholic acid (TUDCA) 5, and their combinations enhanced the regeneration 
of neurites in AGEs-exposed retinas in vitro 9. These findings suggested that they were 
axon-protective agents that could be used to treat neuronal diseases associated with AGEs 
accumulation. The results showed that combinations of citicoline and TUDCA (Doublet) 
and citicoline, TUDCA, and NT-4 (Triplet) significantly increased number of regenerated 
neurites and decreased the number of TUNEL-positive cells. These changes were correlated 
with a decrease in the expressions of caspase-9 and JNK 9 indicating the neuroprotective 
abilities of these agents on cultured retinal cells exposed to advanced glycation end 
products (AGEs) 9. The delivery of neurotrophic factors to the RGCs safely, effectively, and 
for long durations would be best accomplished by topical applications. Several studies have 
been performed using a single neurotrophic factor applied topically to test its 
neuroprotective effect 10-11. The results indicated that citicoline eyedrops can enhance the 
visual function of patients with glaucoma without adverse side effects 12-13. Another recent 
study evaluated the neuroprotective effect of topical citicoline in a mouse model of diabetic 
retinopathy 14. The results indicated that topical citicoline prevented the reduction of the 
retinal thickness in diabetic retinas 14. However, very few attempts have been made using 
combinations of different neurotrophic factors in in vivo studies. Thus, the purpose of this 
study was to determine the neuroprotective and regenerative effects of topical 
administrations of three neurotrophic factors, viz., citicoline, TUDCA, NT-4, used 
individually or in combinations. To accomplish this, the rat optic nerve crush (ONC) model 
was used because it is an easy technique to use for a short period and our prior experience 
with this model 15-16. Furthermore, the mechanisms of the RGC death after optic nerve 
injuries 17-20 are, in part, common with those in our culture system or in degenerating 
neurons 2,4-6,9 of human diabetic retinas 3,21. 
Results 
Brn3a immunopositivity in retinal flat mounts 
To assess the neuroprotective effects of the topical neurotrophic factors, we 
determined the number of surviving RGCs two weeks after the optic nerve was 
crushed. This was done by immunostaining the RGCs with Brn3a, a member of the 
POU-domain transcription factors which is expressed in RGC. The density, cell 
number/mm2, of the RGCs was 4.75 ± 6.63/mm2 in the retina without any treatment, 
which was significantly fewer than the 2280 ± 416.1/mm2 in the normal control (P 
<0.001). In addition to non-operated normal control, we have also checked the 
density of RGCs in sham operated eyes (optic nerve was only exposed without 
crush). The results showed no differences between normal control and sham 
operated eyes in the density of RGCs (P = 0.22, 2280 ± 416.1 versus 2475 ± 
398.0/mm2). The density of RGCs was 847.3 ± 172.7/mm2 in the TUDCA treated 
eyes, 783.9 ± 419.3/mm2 in the citicoline treated eyes, 91.5 ± 66.0/mm2 in the NT-4 
treated eyes, 938.8 ± 477.2/mm2 in the Doublet-1-treated eyes, 1024 ± 223.3/mm2 
in the Doublet-2-treated eyes, and 1215 ± 560.8/mm2 in the Triplet treated eyes. 
The density of RGCs in the citicoline, TUDCA, Doublet-1, Doublet-2, and Triplet 
groups were significantly higher than in the PBS group (P <0.001) (Fig. 1Aa-h, B). 
In the Triplet treated eyes, the density of RGCs was significantly higher than that in 
single drug treated eyes (P = 0.011; citicoline group, P =0.05; TUDCA group, 
P<0.001; NT-4 group). To examine optimal effective doses of drugs, we have also 
performed Brn3a immunostaining of whole retina treated with combined 1mM 
citicoline, 1mM TUDCA, and 1ng/ml NT-4 (low dose Triplet) 2 weeks after ONC. 
The density of RGCs in low dose Triplet treated eyes was 41.99 ± 14.97/mm2 , 
which was significantly lower than that in normal Triplet treated eyes (P < 0.0001) 
and no significant difference was observed between the PBS group and the low 
dose Triplet group (P = 0.3297) (Fig. 1Ai, B). 
 
 
Detection of apoptotic cells in the ganglion cell layer (GCL) 
To evaluate the status of apoptosis after ONC, we compared the number of 
apoptotic cells in the GCL between the PBS group and the Triplet treated group by 
TUNEL staining. In the Triplet treated eyes, the number of TUNEL-positive cells in 
the GCL was significantly lower than that in the PBS group (6.84 ±0.97 % versus 
19.7± 3.6%, P < 0.0001) (Fig. 2) 
 
Neurofilament heavy chain-immunopositive axons in optic nerve 
To investigate the neuroprotective effect of topical neurotrophic factors on axonal 
damage, we counted the number of axons by immunostaining optic nerve sections 
with anti-200kD neurofilament heavy chain (NFH) antibody two weeks after the 
ONC. The numbers of NFH-immunopositive axons decreased to 2.6% in the normal 
control eyes, 8.6% in the citicoline-treated eyes, 17.9% in the TUDCA-treated eyes, 
21.7% in the NT-4-treated eyes, 32.2% in the Doublet-1-treated eyes, 40.3% in the 
Doublet-2-treated eyes, 51.2% in the Triplet-treated eyes (Fig. 3). The number of 
axons was significantly decreased in each group compared with that of the control 
(P <0.001). However, the decrease in the axon number was depressed significantly 
in the combination topical treatment groups (P = 0.004; Doublet-1 group, P <0.001; 
Doublet-2 group, P <0.001; Triplet group). In the Triplet group, the number of 
NFH-immunopositive axons was significantly higher than all of the single treatment 
groups (P <0.001). 
 
Optic nerve regeneration 
Since the Triplet treated eyes have the most protective effect on RGC survival after 
ONC, we assumed that these combined drugs may possibly have axon 
regeneration effect. The regenerating axons of RGCs were detected by GAP-43 
immunostaining at fixed distances from injury site. Two weeks after ONC, the 
number of GAP-43 immunopositive axons in the Triplet treated eyes was greater 
than that in the PBS groups (Fig. 4A, B). The quantitative analyses showed the 
number of regenerating axons that extended beyond 200 μm was 42±19.1 in the 
PBS group compared with 187.3±59.5 in the Triplet group. 
 
Development of adverse events 
Neovascularization of the cornea, iris, and choroid was observed in 8 of 13 rats 
(62%) in the Doublet-1 treated eyes (Fig. 5A). Intense vascular endothelial growth 
factor (VEGF) immunopositive staining was observed in the cryosectioned sclera 
and epiretinal neovascular membranes (Fig. 5B). No adverse effects were found in 
the other groups. 
 
Discussion 
 Citicoline is an intermediate endogenous compound, and it promotes the 
biosynthesis of phospholipids and phosphatidylcholine which are constituents of 
cell membranes. It has been suggested that citicoline inhibits the degradation of 
cardiolipin which is a mitochondrial specific phospholipid of inner membranes and is 
important for mitochondrial function22-23. Thus, the neuroprotective effect of 
citicoline may be as a mitochondrial stabilizer. The results of our earlier animal 
studies suggested that the anti-apoptotic effect of citicoline was involved in 
mitochondria-dependent cell death8. Citicoline also augments tyrosine hydroxylase 
activity and increases the dopamine levels by inhibiting dopamine re-uptake. 
Moreover, citicoline increases the levels of other neurotransmitters, such as 
acetylcholine, noradrenaline, and serotonin24-25. Topical citicoline has already been 
reported to have neuroprotective effect from the results of human preclinical studies 
in glaucomatous optic neuropathy12-13. Currently, citicoline is marketed as a 
neuroprotective eye drop in Europe (Citicoline sodium salt: 0.2 g, hyaluronic acid; 
0.02 g, Benzalkonium chloride 0.001 g water for injection up to 10 ml, OMK1®, 
Omikron Italia, Italy, 3 drops /day). Our study supports the existing data showing the 
neuroprotective effect of citicoline. 
TUDCA is a taurine conjugate formed from ursodeoxycholicacid and is known to 
modulate the function of the endoplasmic reticulum (ER) to protect cells against the 
apoptosis induced by ER stress26. TUDCA reduces ER stress by improving the 
folding capacity of proteins27 and decreasing the level of oxygen free radicals28. The 
results of our earlier study indicated that the neuroprotective and regenerative 
effects of TUDCA were correlated with the suppression of the expression of p-JNK 
which is activated under ER stress through IRE1α 5. In vivo studies have shown that 
TUDCA applied orally or intraperitoneally had neuroprotective effects. In a study of 
RGC degeneration following an intravitreal injection of NMDA, daily intraperitoneal 
injections of TUDCA preserved the RGC function as determined by the scotopic 
threshold response, an ERG component generated by the RGCs29. The results of 
our study support the existing data by showing the neuroprotective effect of TUDCA, 
and this is the first in vivo study showing a neuroprotective effect of TUDCA applied 
topically.NT-4 is a member of the nerve growth factor (NGF) family of proteins along with 
NT-3, brain-derived neurotrophic factor (BDNF) and NGF. NT-4 is believed to act on 
the tyrosine kinase receptor TrkB and BDNF. Upon binding to NT-4 or BDNF, TrkB 
forms dimers, activates an intrinsic kinase activity, evokes autophosphorylation, and 
activates various intracellular signaling cascades including the PI3K/Akt and 
Ras/ERK1/2 pathways. These pathways play an important role on neuroprotection 
and axonal regeneration30-32. Earlier, we investigated the neuroprotective and 
regenerative effects of NT-4 on retinal neurons under diabetic conditions. NT-4 
increased the rate of surviving cells and regenerating neuronal cells in isolated 
retinas incubated in high glucose media4. The neuroprotective effects of NT-4 were 
related to the reduction of cascade-9 and -3 activation, the expression of PERK and 
CHOP, and the expression of c-Jun and JNK6,7. 
 In this study, we showed that crushing the optic nerve led to a loss of RGCs and 
topical application of three neuroprotective agents in combination for 2 weeks twice 
a day had neuroprotective and anti-apoptotic effects on RGCs. An adverse effect of 
simultaneous instillation of 100 mM citicoline and 100 mM TUDCA was the 
development of neovascularization in the cornea, iris, and choroid and the 
formation of epiretinal neovascular membranes. There are several studies that have 
examined the neuroprotective effects of a single neuroprotective agent10-14, but this 
is the first study that examined the neuroprotective effects of a combination these 
three agents.In our previous in vitro study, NT-4 had the most significant neuroprotective 
effect on RGCs in AGEs-exposed retinas 9. However, in this in vivo study, no significant 
neuroprotective effect was found in the NT-4-treated eye. There are two possibilities 
why the effect of NT-4 instillation was reduced; the drug concentration used in this 
study (10 ng/ml) was 10 times lower than in the previous in vitro study 9, and the 
drug concentration at the retina may not have attained a high enough concentration. 
In fact, after topical application of NT-4, the route from the cornea and conjunctiva 
to the retina and optic nerve may be reduced because NT-4 is a protein. This differs 
from that of citicoline and TUDCA which are low molecular weight compounds. 
However, the results of a recent study showed that topical application of NGF, 
which is a larger molecular weight protein than NT-4, was effective in protecting 
RGCs survival and axonal growth two weeks after an ONC in rats16. The results of 
this study indicated that topically applied NGF reached and acted on the structures 
in the posterior segment of the eye. Thus, it is important to determine the factors 
that affect the diffusion and transport of neurotrophic factors through the eye 
structures. In addition, it would be helpful to determine what type of delivery system, 
e.g., an implantation, microspheres or intravitreous injections would be most 
effective in delivering NT-4 to the retina. 
 In the ONC model, the RGC death is preceded by a degeneration of optic nerve due 
to the crush. Thus, it is important to evaluate the changes in the optic nerve. The 
results of staining the sections of the crushed optic nerve with NFH, a nerve-specific 
protein, demonstrated that axonal damage was significantly more suppressed in the 
combined therapy groups than in the monotherapy group. Furthermore, the Triplet 
eye drops have an axon regenerating effect probably due to the increased survival 
of RGCs. Although it may have limited effects on regenerative ability of axons, 
these results suggest additive effects which enhanced the protection of the axons. 
Neovascularization was observed quite regularly only in the combination of 
citicoline and TUDCA group. It was suggested that VEGF production was induced 
by the synergistic effect of the combination of citicoline and TUDCA because strong 
immunopositive signals for VEGF were detected in the sections of the sclera and 
epiretinal membrane in the Doublet-1 treated eyes. Because neovascularization 
was not observed in the Triplet group, we suggest that NT-4 may have suppressed 
the neovascularization. In addition, neovascularization was not noted in the 
individual drug treated groups. Thus, drugs used in this study seem to be safe for 
topical administration individually. However, we could not elucidate why only the 
Doublet-1 treated group developed neovascularization.The results of a study on an animal 
model of cerebral infarction showed that citicoline promoted VEGF production in the 
infarcted area and promoted angiogenesis 33. Because the optic nerve is a part of the central 
nervous system, there is a possibility that inflammatory reactions occurred at the time of the 
ONC, and VEGF production was similarly induced by citicoline instillation. However, 
neovascularization was not observed with citicoline administration alone, and the 
relevance of VEGF production by citicoline instillation is still unknown. Contrary to 
our results, there is a report that VEGF production decreased by one-third after the 
administration of TUDCA in a laser-induced choroidal neovascularization rat 
model 34. Because the ONC is performed by a relatively invasive method and can 
cause inflammatory reactions by itself, it may be useful to test whether 
neovascularization develops with citicoline and TUDCA instillation in different optic 
nerve injury animal models, e.g., NMDA-induced RGCs death model. In addition, it 
will be necessary to determine whether neovascularization occurs in the untreated 
group by citicoline and TUDCA instillation. Future molecular-based research should 
be performed to investigate what type of cells produce VEGF and how the 
molecular mechanisms of neovascularization develop at high rate in the 
combination of citicoline and TUDCA doublet group. 
 There are some limitations in this study. The ONC model does not reflect the 
characteristics of chronic diseases such as glaucoma, optic nerve diseases, and 
diabetic neuropathy because it involves acute optic neurodegenerative changes. 
Our future goal is to determine the neuroprotective effect under the diabetic 
environment by using a diabetic model. One of the challenges of translating the topical 
application to the clinic is how to make drug delivery of these agents more efficient. 
Concentrations of therapeutic agent in the anterior chamber and the vitreous body 
need to be measured to investigate the delivery efficiency of topical application. It 
has been reported that the intravitreal concentration of citicoline after topical 
instillation twice a day for three days was an effective concentration 12. However, 
there is no report about NT-4 and TUDCA in terms of delivery efficiency after topical 
application. 
 
 In conclusion, the results indicate that neuroprotective effects can be promoted and 
axonal regeneration can be achieved with topical instillations of combinations of 
neuroprotective agents. However, we should be aware of possible complications 
such as neovascularization which occurs in the combination of citicoline and 
TUDCA. Further studies to identify the cause of adverse effects need to be 
performed. 
 
Materials and Methods 
 
Animals 
Seven to 10-week-old male Sprague-Dawley (SD) rats (Japan SLC Co., 
Hamamatsu, Japan) were used. All of the procedures were performed in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. The experimental protocol was approved by the Ethics of Animal 
Experiments Committee of Chiba University. 
 
Optic nerve crush (ONC) 
ONC was performed on the left eye of rats under general anesthesia by an 
intraperitoneal injection of a mixture of ketamine (40 mg/kg body weight) and 
xylazine (4 mg/kg/body weight). After anesthesia, an incision was made along the 
midline of the skull to expose the superior surface of the left eye. The optic nerve 
was exposed by removing the superior rectus muscle. The optic nerve was crushed 
with a microvascular clip (Sugita Titanium Aneurysm Clip II) 1 mm posterior to the 
eye for 10 second. Care was taken not to cause retinal ischemia, and this was 
confirmed by indirect ophthalmoscopy through dilated pupils. Forty-two rats were 
divided into 7 groups with 6 animals in each group. The drugs examined were; 100 
mM TUDCA, 100 mM citicoline, 10 ng/ml NT-4, combined TUDCA and citicoline 
(Doublet-1), combined TUDCA and NT4 (Doublet-2) and combined TUDCA, 
citicoline and NT-4 (Triplet), and PBS. The right eyes were used as control. One 
drop of each neurotrophic factor was instilled topically immediately after the 
crushing and then every 12 hours for 14 days. After 2 weeks, the number of 
surviving RGCs was determined by immunostaining flat mounts of retinas with 
anti-Brn3a antibody (Santa Cruz Biotechnology, Inc, CA). Cryosections of 
the optic nerve were immunostained for the anti-200 kD NFH antibody (Abcam, 
Japan) and anti-GAP-43 antibody (Merck Millipore, USA) to study optic nerve 
regeneration after optic nerve crush. We also studied apoptotic status in the GCL by 
TUNEL staining 5 days after ONC. To examine the adverse effects, cryosections of 
the sclera and the epiretinal neovascular membranes were immunostained for 
VEGF (1:1000; Santa Cruz Biotechnology, Inc, CA). 
 
Brn3a-labeled flat mount retina immunohistochemistry (IHC) 
Retinal flat mounts were immunofluorescent stained for Brn3a as described in detail 
35. Animals were euthanized by an overdose of isoflurane, and eyes were 
enucleated, the retinas were isolated, flattened, and fixed in 4% paraformaldehyde 
(PFA) for 1 hour at room temperature. The flat mounts were then washed with 
phosphate buffered saline (PBS) 3 times, blocked with blocking buffer (0.1 M PBS 
with 3% bovine serum and 5% goat serum) for 1 hour then incubated with mouse 
anti-Brn3a monoclonal antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) for at least 24 hours. The whole mount retinas were then incubated with fluorescein 
isothiocyanate-conjugated anti-mouse IgG at 4 º C overnight. The number of Brn3a 
immunopositive cells was counted in four areas randomly selected at a distance of 
2 mm from the optic disc (330 μm × 450 μm). The mean number of RGCs/mm2 was 
calculated. 
 
TUNEL Staining 
Five days after ONC, Rats were given an overdose of general anesthesia and were 
perfused transcardially with PBS followed by 4%PFA. Eyeballs were dissected 
immediately and immersion-fixed 4%PFA for 2h. Retinas were transferred 30% 
(wt/vo) sucrose for at least 24hours, embedded in an optimal cutting temperature 
compound for frozen tissue specimens (Tissue-Tek OCT compound; Sakura 
Finetechnical Co. Ltd., Tokyo, Japan), and sectioned with a cryostat. TUNEL 
staining was performed with an apoptosis detection kit (Chemicon International, 
Temecula, CA) following the manufacturer’s instruction. Hoechst 33342 nucleic acid 
was used (1:1000) for nuclear counterstain. For quantitative analyses, the ratio of 
the number of TUNEL-positive cells to the total number of nuclear staining in the 
GCL was determined. 
 
Immunohistochemical staining of optic nerves 
Fourteen days after ONC, Rats were given an overdose of general anesthesia and 
were perfused transcardially with 4%PFA. Segments of the optic nerves (8-10 mm) 
between optic nerve head and optic chiasma were collected. The nerves were 
post-fixed in 4%PFA at 4º C for 24 hours, washed with PBS, and immersed in 30% 
sucrose for at least 24 hours at 4º C. The optic nerves were embedded in an OCT 
compound. For GAP-43 immunostaining, optic nerves were Cryostat-sectioned 
longitudinally at 14 μm, mounted on glass slides. After blocking the sections in 0.1 M 
PBS with 3% bovine serum and 5% goat serum at RT for 1h, they were incubated 
with the anti-GAP-43 antibody (1:2000; Merck Millipore, USA) at 4º C overnight, followed 
by fluorescently labeled secondary antibody. Axons were counted at fixed distances 
from the injury site in 3 sections per nerve to estimate the total number of 
regenerating axons 36. For anti-200 kD NFH antibody immunostaining, optic nerves were 
cross-sectioned at 14μm, mounted on glass slides. To determine the numbers of 
NFH immunopositive axons in each group, each immunostained sample was used 
for axon counting. For that purpose, 10-12 sections per group were used. Sections 
were prepared at the 0.5mm distal site from the crush level. The fluorescent images 
were photographed with a fluorescence microscope with a 40X objective lens. The 
number of axons was determined in at least four areas of 36,960 μm2 (165 μm × 
224 μm) from each eye. The acquired images were quantified by the Image J 
software 37. We have counted the number of the minimal units of axonal bundles in 
the areas. After being quantified by Image J software, dot-like signals were 
disappeared. Thus, nonspecific signals such as dot-like staining were not included 
in this analysis. 
 
Statistical analyses 
All measurements were performed in a masked fashion. Statistical analyses were 
performed by one-way analysis of variance with Tukey's multiple comparisons 
tests for comparisons between each group. Data are presented as the means ± 
standard deviation (S.D). A P <0.05 was considered statistically significant. 
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Figure legends:  
Figure 1. Effects of the three NFs on RGC degeneration following ONC.  
(A) Representative photomicrographs of Brn3a immunopositive cells in the flat mount 
retina. a: normal, b: PBS (ONC+PBS), c: citicoline (ONC+citicoline), d: TUDCA 
(ONC+TUDCA), e: NT-4 (ONC+NT-4), f: Doublet-1 (ONC+citicoline+TUDCA), g: 
Doublet-2 (ONC+TUDCA+NT-4), h: Triplet (ONC+citicoline+TUDCA+NT4). i: Low 
dose Triplet (Scale Bar: 50μm.) (B) Graph showing RGC count (cells/mm2) of each group 
two weeks after ONC. The densities of RGCs in all of the eyes except NT-4 and low dose 
triplet group were significantly higher than those of RGCs without treatment. (** :P<0.001) 
Values represent means ± SEM of n=6 animals per experimental group. Significances of 
intergroup differences were evaluated by one-way ANOVA with Tukey’s multiple 
comparisons test. 
 
Figure 2. Quantification of apoptosis in the retina following ONC determined by 
TUNEL staining. (A) Representative photomicrographs of TUNEL positive cells in the 
ganglion cell layer (GCL) in normal control, PBS and Triplet-treated rats at 5 days 
after ONC. (Scale Bar: 20μm) (B) Graph showing the ratio of the number of TUNEL-
positive cells to the total number of retinal neuronal cells in the GCL after ONC. Compared 
with the untreated PBS group, TUNEL positive ratio was decreased significantly in the 
Triplet eye drop treatment group (**: P<0.001). Values represent means ± SEM of 
n=3 animals per experimental group. 
 
Figure 3. Effects of the three NFs on axonal degeneration following ONC.  
(A) Representative photomicrographs of NFH-immunopositive axons in 
the optic nerve. a: normal, b: PBS, c: citicoline, d: TUDCA, e: NT-4, f: Doublet-1 
(ONC+citicoline+TUDCA), g: Doublet-2 (ONC+TUDCA+NT-4), h: Triplet 
(ONC+citicoline+TUDCA+NT-4). (Scale Bar: 50 μm.) (B) Graph showing average 
number of NFH immunopositive axon counts. Compared with the untreated group, 
the decrease in axon number was suppressed significantly in the combination eye 
drop treatment group. (*: P<0.05; Doublet-1 group, **: P<0.001; Doublet-2 group 
and Triplet group.) Values represent means ± SEM of n=3-4 animals per 
experimental group. Significances of intergroup differences were evaluated by 
one-way ANOVA with Tukey's multiple comparisons test. N, normal control; 
Doublet-1, citicoline+TUDCA; Doublet-2, TUDCA+NT-4; Triplet, 
citicoline+TUDCA+NT-4 
 
Figure 4. Triplet instillation induces axonal regeneration after ONC. (A) Sagittal 
sections through the optic nerve showing GAP-43-labeled axons distal to the 
injury site (dotted line) in PBS and triplet-treated rats at 2 weeks after ONC. 
Arrowheads indicate regenerating axons. (Scale bar:100 μm) (B) Higher 
magnification of the images shown in figure A. (Scale bar:50 μm) (C) Graph 
showing quantification of regenerating axons at different distances distal to the 
lesion site (*: P<0.05). Values represent means ± SEM of n=3 animals per 
experimental group. 
 
Figure 5. Side effect of eye drop administration of combined TUDCA and citicoline 
following ONC. (A) Representative photographies of iris, retina, and sclera in Doublet-1 
group. Neovascularizations of the cornea, iris, and choroid were observed in 8 of 13 
rats (62%) in the Doublet-1 treated eyes. a: Iris, b: Retina and epiretinal neovascular 
membrane (*), c: Choroid and sclera (B) Representative photomicrographs of 
VEGF-immunopositive sclera and epiretinal membrane in the Doublet-1 treated eye. 
Intense VEGF immunopositive signaling was observed in the sections of sclera, 
choroidal vessels (arrowhead) and epiretinal neovascular membranes (*) Scale 
Bar: 20 μm. 
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